Breaking News, Collaborations & Alliances

FDA Approves Viatris’ Generic Version of Symbicort

The complex generic inhalation aerosol named Breyna was made in partnership with the CDMO Kindeva Drug Delivery.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Viatris and Kindeva Drug Delivery have revealed that Mylan Pharmaceuticals, a Viatris subsidiary, has received approval from the U.S. FDA for its abbreviated new drug application (ANDA) for Breyna (budesonide and formoterol fumarate dihydrate inhalation aerosol), the first approved generic version of AstraZeneca’s Symbicort. Breyna, a drug-device combination product, is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD) and will be available in 160 m...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters